The production of anti-Zika virus (ZIKV) therapeutics has become increasingly important as the propagation of the 31 devastating virus continues largely unchecked. Notably, a causal relationship between ZIKV infection and 32 neurodevelopmental abnormalities has been widely reported, yet a specific mechanism underlying impaired 33 neurological development has not been identified. Here, we report on the design of several synthetic competitive 34 inhibitory peptides against key pathogenic ZIKV proteins through the prediction of protein-protein interactions (PPIs).
Introduction

42
The Zika virus (ZIKV) is currently causing an ongoing pandemic, incurring considerable human impact. The rapid 43 spread of the virus throughout the Western hemisphere has driven a significant accumulation of knowledge on ZIKV 44 infection [1] [2] [3] [4] . The ZIKV is a positive-sense single stranded RNA (+ssRNA) arbovirus from the genus Flavivirus 45 [5, 6] . A mature ZIKV virion contains a monopartite segment of +ssRNA 10,800 nucleotides enclosed in a capsid 46 comprised of C-proteins and surrounded by a 50 nm spherical envelope. The membrane is comprised of membrane (M) and envelope (E) proteins arranged around the icosahedral capsid. The entire genome is translated in to a single DeNovo is a host-virus PPI prediction tool tailored to predict cross-species protein interactions for newly identified viral organisms for which no interaction data are previously known [25] . Given the lack of known interactions for the protein (and their associated ZIKV interactors) from our list of 209 candidates based on their correlation to known mechanisms of ZIKV infection, pathology, and symptomology. Of the eleven ZIKV proteins considered, the nine dependent RNA polymerase NS5 proteins. These proteins not only highlight protein candidates for PPI-based 117 therapeutic design, but also they may provide potential mechanisms of ZIKV infection. [54] SNAP25 (N) NS4B, M Huntington's Disease (D) [55] YWHAE (N) NS4B Neurocognitive, Cerebrospinal fluid marker (D) [56] COX17 (N) NS4B, NS2A Cardiomyopathy, hepatic failure (D) [57] SPZ1 (N) NS4B, M Spermatogenesis (F) [58] DNAJA1 (N) Pr, M Testis development, spermatogenesis (F) [59] * indicates interaction pairs also predicted for the Dengue virus. moves to the cell membrane. 5: The ZIKV particle exits the host cell. P3 may also interfere with these last two steps.
192
The ENO2 interaction with NS5 may impact neurodevelopment. This is the proposed site of P2 activity. The predicted 193 interaction between RNASET2 and NS3, which we hypothesize to cleave the RNASET2 functional protein at amino inhibitor for the NS5 binding site. In this way, we predict that P2 will interrupt the lifecycle of the ZIKV in the human 207 cell, thus acting as an effective therapeutic.
208
A previous study identified AXL as a receptor candidate that is active in the ZIKV lifecycle [70]. Although not a 209 receptor, TRAF4 is an essential element for normal TNF receptor function as TRAFs have been previously identified 210 as adaptor proteins for membrane receptors [71] . Therefore, it is possible that the ZIKV M protein may be impacting 211 functionality of the TNF receptor via TRAF4, possibly increasing the function of TNF. Pertaining to 212 neurodevelopment, it has been shown that TRAF4 is required for normal neural crest formation [46] . If the ZIKV M 213 protein is binding to TRAF4 in a inhibitory manner, it is possible that TNF receptor functionality may be impacted 214 [71] , and that neural crest formation may be negatively affected [46] . The corresponding PPI-Site derived peptide for Finally, a short motif within centrosomal protein CEP63 was predicted to interact with the ZIKV serine protease NS3.
dysfunctional. Overproduction of P4 may be able to saturate NS3 activity and prevent detrimental proteolytic cleavage 222 of the endogenous target.
223
In this study, we have identified proteins and PPI-Sites of interest and designed a series of peptides that could be used 
